Australia - inglese - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 0.02 % - solution, irrigation - excipient ingredients: glacial acetic acid; water for injections - chlorhexidine acetate (0.02 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

phytoceuticals pty ltd - natural fish oil, quantity: 1 g (equivalent: eicosapentaenoic acid, qty 180 mg; equivalent: docosahexaenoic acid, qty 120 mg) - capsule, soft - excipient ingredients: sucralose; orange oil; lecithin; d-alpha-tocopherol; glycerol; purified water; sunset yellow fcf; titanium dioxide; gelatin - temporary relief of the pain of arthritis. (or) temporary relief of arthritic pain. [warning s required] may help reduce joint inflammation associated with arthritis. may assist blood circulation. aids or assists in the maintenance of peripheral circulation. may assist in maintaining peripheral circulation and promoting general health. may assist in the management of dry skin. for the symptomatic relief of dry skin. aids, assists or helps in the maintenance or improvement of general well-being.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - trifolium pratense -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

h c l manufacturers pty ltd - royal jelly -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - clindamycin hydrochloride, quantity: 10 mg/ml - solution - excipient ingredients: dioctyl malate; purified water; ethanol - clindtech solution is indicated for the topical treatment of acne vulgaris, particularly forms in which comedones, papules and pastules predominate.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; silicon dioxide; magnesium stearate; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil, quantity: 500 microgram/ml - injection, solution - excipient ingredients: ethanol - indications as at 14 january 1994: prostin vr sterile solution (alprostadil) is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, mitral atresia, or transposition of the great vessels with or without other defects. prostin vr should be administered only by medically trained personnel in facilities in which paediatric patients can receive or have access to paediatric intensive care.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: guar gum; titanium dioxide; purified talc; sodium calcium edetate; iron oxide red; citric acid; quinoline yellow aluminium lake; hypromellose; ethylcellulose; propylene glycol; carnauba wax; magnesium stearate; powdered cellulose; colloidal anhydrous silica; citric acid monohydrate - hypertension (mild, moderate to severe).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium acetate, quantity: 1.28 g/l; sodium chloride, quantity: 2.34 g/l; magnesium acetate tetrahydrate, quantity: 320 mg/l; glucose, quantity: 50 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - plasma-lyte 56 and 5% glucose iv infusion is indicated as a source of water, electrolytes and calories or as an alkalinising agent. plasma-lyte 56 in 5% glucose is indicated as a source of water and electrolytes or as an alkalinising agent.